Latest news with #CignaGroup
Yahoo
26-05-2025
- Business
- Yahoo
UBS Maintains Buy Rating on Cigna (CI) Stock
On Friday, May 23, UBS analyst AJ Rice reaffirmed a 'Buy' rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views after a recent investor event at the Evernorth Innovation Lab, which was held together with the company's management team. The Cigna Group's (NYSE:CI) strategic departure from the Medicare Advantage (MA) business was highlighted. The company's management showed strong confidence regarding the current mix of businesses, which includes commercial healthcare, pharmacy benefit management, and specialty drug and other care services. A healthcare team discussing strategies for patient advocacy programs. Rice expressed confidence that The Cigna Group (NYSE:CI) can continue to achieve its goal of low-double-digit earnings growth. This positive outlook is in part because the company is strategically moving away from the difficulties linked to government-related healthcare programs. The analyst's report emphasized the company's diverse business portfolio as a key strength. A key topic at the event was The Cigna Group's (NYSE:CI) GLP1 program. Rice discussed this program, which is for clients who do not currently cover GLP1 medications for weight management. This represents about half of Evernorth's clients. The program aims to make GLP1 treatments more accessible by sharing costs fairly between the plan sponsor and the patients, while also offering a lower net cost of these drugs for all clients. According to Rice, this program will help both clients and patients by offering more accessible treatment options and managing costs effectively. The Cigna Group (NYSE:CI) is a global health company that operates through two divisions, Cigna Healthcare and Evernorth Health Services. The company has sales capabilities in over 30 markets and jurisdictions. While we acknowledge the potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CI and that has a 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Sign in to access your portfolio
Yahoo
26-05-2025
- Business
- Yahoo
UBS Maintains Buy Rating on Cigna (CI) Stock
On Friday, May 23, UBS analyst AJ Rice reaffirmed a 'Buy' rating on The Cigna Group (NYSE:CI) with a price target of $390. Rice shared his views after a recent investor event at the Evernorth Innovation Lab, which was held together with the company's management team. The Cigna Group's (NYSE:CI) strategic departure from the Medicare Advantage (MA) business was highlighted. The company's management showed strong confidence regarding the current mix of businesses, which includes commercial healthcare, pharmacy benefit management, and specialty drug and other care services. A healthcare team discussing strategies for patient advocacy programs. Rice expressed confidence that The Cigna Group (NYSE:CI) can continue to achieve its goal of low-double-digit earnings growth. This positive outlook is in part because the company is strategically moving away from the difficulties linked to government-related healthcare programs. The analyst's report emphasized the company's diverse business portfolio as a key strength. A key topic at the event was The Cigna Group's (NYSE:CI) GLP1 program. Rice discussed this program, which is for clients who do not currently cover GLP1 medications for weight management. This represents about half of Evernorth's clients. The program aims to make GLP1 treatments more accessible by sharing costs fairly between the plan sponsor and the patients, while also offering a lower net cost of these drugs for all clients. According to Rice, this program will help both clients and patients by offering more accessible treatment options and managing costs effectively. The Cigna Group (NYSE:CI) is a global health company that operates through two divisions, Cigna Healthcare and Evernorth Health Services. The company has sales capabilities in over 30 markets and jurisdictions. While we acknowledge the potential of CI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CI and that has a 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: 11 Stocks That Will Bounce Back According To Analysts and 11 Best Stocks Under $15 to Buy According to Hedge Funds. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Why Hims & Hers Health (HIMS) Stock Is Falling Today
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.3% in the afternoon session after Cigna Group's Evernorth division introduced a monthly $200 price cap for weight-loss medications such as Wegovy and Zepbound, a move that could significantly disrupt pricing in the weight loss drug market. For Hims & Hers, which offers both compounded Semaglutide and branded GLP-1 treatments, this introduces a direct competitive threat, particularly if Evernorth's pricing becomes a benchmark in the industry. The shares closed the day at $53.52, down 7.7% from previous close. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Hims & Hers Health? Access our full analysis report here, it's free. Hims & Hers Health's shares are extremely volatile and have had 94 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 16 days ago when the stock gained 20.2% on the news that the company reported strong first quarter 2025 results which significantly beat analysts' expectations on revenue, EPS, and EBITDA. Sales more than doubled from the previous year driven by higher monthly spending per subscriber and a broader product mix tailored to personalized health needs. While subscriber growth slowed to 38% year over year, average revenue per user climbed over 50%, indicating deeper wallet share from existing customers and more engagement with premium offerings. On the other hand, revenue guidance was softer than anticipated. Still, we think this was a decent quarter. Hims & Hers Health is up 112% since the beginning of the year, but at $53.35 per share, it is still trading 22.4% below its 52-week high of $68.74 from February 2025. Investors who bought $1,000 worth of Hims & Hers Health's shares 5 years ago would now be looking at an investment worth $5,340. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
Yahoo
23-05-2025
- Business
- Yahoo
Cigna Announced a New Agreement for Copay Caps on Eli Lilly and Novo Nordisk Weight Loss Drugs
The Cigna Group (NYSE:CI)'s Evernorth division has announced a new deal with Novo Nordisk and Eli Lilly that will limit insured customers' monthly out-of-pocket expenses for weight-loss drugs Zepbound and Wegovy to $200. A healthcare team discussing strategies for patient advocacy programs. Beginning in the second half of 2025, the program targets businesses that do not already cover these drugs because of their high price tag. Harold Carter, senior vice president at Evernorth, stated the agreement guarantees uniform pricing for pharmacies and Evernorth's home delivery while streamlining pre-authorization. The GLP-1 drugs are currently only covered by half of The Cigna Group (NYSE:CI)'s clients. Customers who now provide coverage could save as much as 20%. The agreement comes after Lilly's Zepbound was essentially sidelined when CVS Caremark said in April that Wegovy was its preferred weight-loss medication. According to analysts, net discounts for employers on list prices range from 30% to 50%. Zepbound lists at $1,100 with a $725 net price; Wegovy lists at $1,350/month but averaged $616 net in March. When compared to cash expenditures made out of pocket, the new caps offer savings of over 50%. Evernorth's action is in advance of the Inflation Reduction Act's 2027 Medicare drug pricing reductions, which will benefit Novo's products. Eli Lilly states that it remains committed to expanding industry collaboration to improve access to Zepbound. While we acknowledge the potential of CI to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CI and that has 100x upside potential, check out our report about this READ NEXT: and . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month
Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients ST LOUIS, May 21, 2025 /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE: CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to patients. Through direct negotiations with the medications' manufacturers, Evernorth has ensured that patients' monthly cost will not exceed $200. "We are reimagining pharmacy benefits to reduce costs and better serve patients," said Adam Kautzner, Pharm D, President of Evernorth Care Management and Express Scripts. "This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals." This initiative fills a critical need in the market by offering savings, choice and predictability to both patients and health plan sponsors. Benefits for Patients: Lower Monthly Copays than Cash Programs: The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient's annual deductible. Meaningful Savings: Patients can save as much as $3,600 per year compared to buying these medications directly from manufacturers or through consumer programs. Enhanced Safety and Efficacy: By accessing WEGOVY® or ZEPBOUND® through Evernorth's pharmacy benefit, patients will benefit from FDA-approved medications and Express Scripts' robust safety checks designed to reduce negative or adverse drug interactions. Simplified Approval and Access: The prior authorization processes accompanying the new offering will be simplified and automated for faster access. Choice of Pharmacies: Patients can select from a broad network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy, staffed by clinicians with specialized knowledge in GLP-1s for enhanced support. Benefits for Employers & Other Health Plan Sponsors: Significant Cost Reduction: Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications. Offering Patient Options: Health plan sponsors can ensure that patients have access to the medication that works best for them, without compromising affordability or clinical safety. "As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and we're making it easier than ever for health plan sponsors to cover GLP-1s for weight loss," said Harold Carter, PharmD, senior vice president of trade relations at Express Scripts. "This is how we deliver on our promise to put patients first - by making innovative medicines more accessible, at a lower cost, while providing patients and physicians choices in this fast-evolving market." Evernorth has the most extensive suite of GLP-1 solutions available with this new addition, which also includes: EncircleRx, a financial model with more than 9 million enrolled lives that has saved health plans $200 million dollars since 2024. EnReachRx, a high-touch patient support clinical model for dispensing GLP-1 prescription medications. About Evernorth Health Services Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE: CI), or third-party partners. Learn more at Media Contact:Justine View original content to download multimedia: SOURCE Evernorth Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
